Key Points
-
Tremendous advances have been made in the discovery of novel ligands for G-protein-coupled receptors (GPCRs) that act at allosteric sites to regulate receptor function.
-
Small molecules can act at allosteric sites to directly activate the receptor (allosteric agonists) or to potentiate (positive allosteric modulators) or inhibit (negative allosteric modulators) responses to traditional GPCR agonists that act at the orthosteric site.
-
Allosteric modulators of GPCRs often provide higher selectivity for individual GPCR subtypes than has been achieved with traditional orthosteric-site ligands.
-
Allosteric ligands can provide novel modes of efficacy that are not possible with orthosteric-site ligands and may provide advantages as therapeutic agents, such as allosteric potentiator and partial antagonist activity.
-
Two allosteric modulators that are not marketed for treatment of human disorders and multiple allosteric modulators are now advancing in discovery and clinical development programmes.
-
Allosteric modulators may lead to novel therapeutic agents for treatment of multiple psychiatric and neurological disorders, including anxiety disorders, schizophrenia and Alzheimer's disease.
Abstract
Despite G-protein-coupled receptors (GPCRs) being among the most fruitful targets for marketed drugs, intense discovery efforts for several GPCR subtypes have failed to deliver selective drug candidates. Historically, drug discovery programmes for GPCR ligands have been dominated by efforts to develop agonists and antagonists that act at orthosteric sites for endogenous ligands. However, in recent years, there have been tremendous advances in the discovery of novel ligands for GPCRs that act at allosteric sites to regulate receptor function. These compounds provide high selectivity, novel modes of efficacy and may lead to novel therapeutic agents for the treatment of multiple psychiatric and neurological human disorders.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
George, S. R., O'Dowd, B. F. & Lee, S. P. G-protein-coupled receptor oligomerization and its potential for drug discovery. Nature Rev. Drug Discov. 1, 808–820 (2002).
Spiegel, A. M. Mutations in G proteins and G protein-coupled receptors in endocrine disease. J. Clin. Endocrinol. Metab. 81, 2434–2442 (1996).
Rana, B. K., Shiina, T. & Insel, P. A. Genetic variations and polymorphisms of G protein-coupled receptors: functional and therapeutic implications. Annu. Rev. Pharmacol. Toxicol. 41, 593–624 (2001).
Howard, A. D. et al. Orphan G-protein-coupled receptors and natural ligand discovery. Trends Pharmacol. Sci. 22, 132–140 (2001).
Mohler, H. F., Fritschy, J. M. & Rudolph, U. A new benzodiazepine pharmacology. J. Pharmacol. Exp. Ther. 300, 2–8 (2002).
Langmead, C. J. & Christopoulos, A. Allosteric agonists of 7TM receptors: expanding the pharmacological toolbox. Trends Pharmacol. Sci. 27, 475–481 (2006).
May, L. T., Leach, K., Sexton, P. M. & Christopoulos, A. Allosteric modulation of G protein-coupled receptors. Annu. Rev. Pharmacol. Toxicol. 47, 1–51 (2007). Comprehensive overview of principles, mechanisms and examples of GPCR allosterism.
Lazareno, S. & Birdsall, N. J. Detection, quantitation, and verification of allosteric interactions of agents with labeled and unlabeled ligands at G protein-coupled receptors: interactions of strychnine and acetylcholine at muscarinic receptors. Mol. Pharmacol. 48, 362–378 (1995).
Ehlert, F. J. Estimation of the affinities of allosteric ligands using radioligand binding and pharmacological null methods. Mol. Pharmacol. 33, 187–194 (1988).
Hall, D. A. Modeling the functional effects of allosteric modulators at pharmacological receptors: an extension of the two-state model of receptor activation. Mol. Pharmacol. 58, 1412–1423 (2000). Together with reference 9, important theoretical papers describing the application and extension of the ternary complex model to allosteric interactions.
Christopoulos, A. & Kenakin, T. G protein-coupled receptor allosterism and complexing. Pharmacol. Rev. 54, 323–374 (2002).
Christopoulos, A. Allosteric binding sites on cell-surface receptors: novel targets for drug discovery. Nature Rev. Drug Discov. 1, 198–210 (2002).
Lazareno, S., Dolezal, V., Popham, A. & Birdsall, N. J. Thiochrome enhances acetylcholine affinity at muscarinic M4 receptors: receptor subtype selectivity via cooperativity rather than affinity. Mol. Pharmacol. 65, 257–266 (2004).
Valant, C. et al. A novel mechanism of G protein-coupled receptor functional selectivity: Muscarinic partial agonist McN-A-343 as a bitopic orthosteric/allosteric ligand. J. Biol. Chem. (2008). Discovery and validation of a bitopic orthosteric/allosteric mode of action of a functionally selective GPCR ligand.
Kenakin, T. New concepts in drug discovery: collateral efficacy and permissive antagonism. Nature Rev. Drug Discov. 4, 919–927 (2005).
Urban, J. D. et al. Functional selectivity and classical concepts of quantitative pharmacology. J. Pharmacol. Exp. Ther. 320, 1–13 (2007).
Mathiesen, J. M. et al. Identification of indole derivatives exclusively interfering with a G protein-independent signaling pathway of the prostaglandin D2 receptor CRTH2. Mol. Pharmacol. 68, 393–402 (2005). One of the earliest and most striking examples of allosteric modulator-mediated stimulus trafficking.
Zhang, Y., Rodriguez, A. L. & Conn, P. J. Allosteric potentiators of metabotropic glutamate receptor subtype 5 have differential effects on different signaling pathways in cortical astrocytes. J. Pharmacol. Exp. Ther. 315, 1212–1219 (2005).
Leach, K., Sexton, P. M. & Christopoulos, A. Allosteric GPCR modulators: taking advantage of permissive receptor pharmacology. Trends Pharmacol. Sci. 28, 382–389 (2007).
May, L. T. & Christopoulos, A. Allosteric modulators of G-protein-coupled receptors. Curr. Opin. Pharmacol. 3, 551–556 (2003).
Harrington, P. E. & Fotsch, C. Calcium sensing receptor activators: calcimimetics. Curr. Med. Chem. 14, 3027–3034 (2007).
Dorr, P. et al. Maraviroc (UK-427, 857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity. Antimicrob. Agents Chemother. 49, 4721–4732 (2005).
Kola, I. & Landis, J. Can the pharmaceutical industry reduce attrition rates? Nature Rev. Drug Discov. 3, 711–715 (2004).
Conn, P. J. & Pin, J. P. Pharmacology and functions of metabotropic glutamate receptors. Annu. Rev. Pharmacol. Toxicol. 37, 205–237 (1997).
Romano, C., Sesma, M. A., Mcdonald, C. T., O'Malley, K., Van den Pol., A. N. & Olney, J. W. Distribution of metabotropic glutamate receptor mGluR5 immunoreactivity in rat brain. J. Comp. Neurol. 355, 455–469 (1995).
Valenti, O., Conn, P. J. & Marino, M. J. Distinct physiological roles of the Gq-coupled metabotropic glutamate receptors Co-expressed in the same neuronal populations. J. Cell Physiol. 191, 125–137 (2002).
Annoura, H., Fukunaga, A., Uesugi, M., Tatsouka, T. & Horikawa, Y. A novel class of antagonists for metabotropic glutamate receptors, 7-(hydroxyimino)cyclopropchromen-1acarboxylates. Bioorg Med. Chem. Lett. 6, 763–766 (1996).
Varney, M. A. et al. SIB-1757 and SIB-1893: selective, noncompetitive antagonists of metabotropic glutamate receptor type 5. J. Pharmacol. Exp. Ther. 290, 170–181 (1999). Together with reference 27, seminal papers reporting the discovery of early, novel GPCR negative allosteric modulators (NAMS) for metabotropic glutamate receptors.
Gasparini, F. et al. 2-Methyl-6-(phenylethynyl)-pyridine (MPEP), a potent, selective and systemically active mGlu5 receptor antagonist. Neuropharmacology 38, 1493–1503 (1999).
Cosford, N. D. et al. 3-[(2-Methyl-1, 3-thiazol-4-yl)ethynyl]-pyridine: a potent and highly selective metabotropic glutamate subtype 5 receptor antagonist with anxiolytic activity. J. Med. Chem. 46, 204–206 (2003).
Lea, P. M. & Faden, A. I. Metabotropic glutamate receptor subtype 5 antagonists MPEP and MTEP. CNS Drug Rev. 12, 149–166 (2006).
Yu, M. Recent developments of the PET imaging agents for metabotropic glutamate receptor subtype 5. Curr. Top. Med. Chem. 7, 1800–1805 (2007).
Swanson, C. J. et al. Metabotropic glutamate receptors as novel targets for anxiety and stress disorders. Nature Rev. Drug Discov. 4, 131–144 (2005).
Porter, R. H. et al. Fenobam: a clinically validated nonbenzodiazepine anxiolytic is a potent, selective, and noncompetitive mGlu5 receptor antagonist with inverse agonist activity. J. Pharmacol. Exp. Ther. 315, 711–721 (2005).
Patel, J. B., Martin, C. & Malick, J. B. Differential antagonism of the anticonflict effects of typical and atypical anxiolytics. Eur. J. Pharmacol. 86, 295–298 (1982).
Pecknold, J. C., McClure, D. J., Appeltauer, L., Wrzesinski, L. & Allan, T. Treatment of anxiety using fenobam (a nonbenzodiazepine) in a double-blind standard (diazepam) placebo-controlled study. J. Clin. Psychopharmacol. 2, 129–133 (1982).
Bear, M. F., Huber, K. M., Warren, S. T. The mGluR theory of fragile X mental retardation. Trends Neurosci. 27, 370–377 (2004).
Slassi, A. et al. Recent advances in non-competitive mGlu5 receptor antagonists and their potential therapeutic applications. Curr. Top. Med. Chem. 5, 897–911 (2005).
Kinney, G. G., Burno, M., Campbell, U. C., Hernandez, L. M., Rodriguez, D., Bristow, L. J. & Conn, P. J. Metabotropic glutamate subtype 5 receptors modulate locomotor activity and sensorimotor gating in rodents. J. Pharmacol. Exp. Ther. 306, 116–123 (2003).
Campbell, U. C., Lalwani, K., Hernandez, L., Kinney, G. G., Conn, P. J. & Bristow, L. J. The mGluR5 antagonist 2-methyl-6-(phenylethynyl)-pyridine (MPEP) potentiates PCP-induced cognitive deficits in rats. Psychopharmacology (Berl.) 175, 310–318 (2004).
Rodriguez, A. et al. A close structural analog of 2-methyl-6-(phenylethynyl)-pyridine acts as a neutral allosteric site ligand on metabotropic glutamate receptor subtype 5 and blocks the effects of multiple allosteric modulators. Mol. Pharmacol. 68, 1793–1802 (2005). This study reports the initial discovery of a GPCR NAM that has partial antagonist activity as well as being a novel, neutral allosteric-site ligand.
Marino, M. J. & Conn, P. J. Direct and indirect modulation of the N-methyl D-aspartate receptor. Curr. Drug Target CNS Neurol. Disord. 1, 1–16 (2002).
Moghaddam, B. Targeting metabotropic glutamate receptors for treatment of the cognitive symptoms of schizophrenia. Psychopharmacology (Berl.) 174, 39–44 (2004).
Alagarsamy, S., Sorensen, S. D. & Conn, P. J. Coordinate regulation of metabotropic glutamate receptors. Curr. Opin. Neurobiol. 11, 357–362 (2001).
Mannaioni, G., Marino, M. J., Valenti, O., Traynelis, S. F. & Conn, P. J. Metabotropic glutamate receptors 1 and 5 differentially regulate CA1 pyramidal cell function. J. Neurosci. 21, 5925–5934 (2001).
Lindsley, C. W. et al. Progress towards validating the NMDA receptor hypofunction hypothesis of schizophrenia. Curr. Top. Med. Chem. 6, 771–785 (2006).
Alagarsamy, S., Marino, M. J., Rouse, S. T., Gereau, R. W., Heinemann, S. F. & Conn, P. J. Activation of NMDA receptors reverses desensitization of mGluR5 in native and recombinant systems. Nature Neurosci. 2, 234–240 (1999a).
O'Brien, J. A. et al. A family of highly selective allosteric modulators of the metabotropic glutamate receptor subtype 5. Mol. Pharmacol. 64, 731–740 (2003). Initial discovery of mGluR5-positive allosteric modulators (PAMs) and demonstration that compounds in a single structural class can have PAM, NAM and neutral allosteric site activity.
O'Brien, J. A. et al. A novel selective allosteric modulator potentiates the activity of native metabotropic glutamate receptor subtype 5 in rat forebrain. J. Pharmacol. Exp. Ther. 309, 568–577 (2004).
Lindsley, C. W. et al. Discovery of positive allosteric modulators for the metabotropic glutamate receptor subtype 5 from a series of N-(1, 3-diphenyl-1H- pyrazol-5-yl)benzamides that potentiate receptor function in vivo. J. Med. Chem. 47, 5825–5828 (2004).
Kinney, G. G. et al. A novel selective positive allosteric modulator of metabotropic glutamate receptor subtype 5 has in vivo activity and antipsychotic-like effects in rat behavioral models. J. Pharmacol. Exp. Ther. 313, 199–206 (2005).
Zhao, Z. et al. Challenges in the development of mGluR5 positive allosteric modulators: the discovery of CPPHA. Bioorg Med. Chem. Lett. 17, 1386–1391 (2007).
Chen, Y. et al. Interaction of novel positive allosteric modulators of metabotropic glutamate receptor 5 with the negative allosteric antagonist site is required for potentiation of receptor responses. Mol. Pharmacol. 71, 1389–1398 (2007).
Chen, Y., Goudet, C., Pin, J. P. & Conn, P. J. N-{4-Chloro-2-[(1, 3-dioxo-1, 3-dihydro-2H-isoindol-2-yl)methyl]phenyl}-2-hydroxybenzamide (CPPHA) acts through a novel site as a positive allosteric modulator of group 1 metabotropic glutamate receptors. Mol. Pharmacol. 73, 909–18 (2008).
de Paulis, T. et al. Substituent effects of N-(1, 3-diphenyl-1 H-pyrazol-5-yl) benzamides on positive allosteric modulation of the metabotropic glutamate-5 receptor in rat cortical astrocytes. J. Med. Chem. 49, 3332–3344 (2006).
Epping-Jordan, M. P. et al. In vivo characterization of mGluR5 positive allosteric modulators as novel treatments for schizophrenia and cognitive dysfunction. Neuropharmacol. 49, 243 (2005).
Darrah, J. M., Stefani, M. R. & Moghaddam, B. Interaction of N-methyl-D-aspartate and group 5 metabotropic glutamate receptors on behavioral flexibility using a novel operant set-shift paradigm. Behav. Pharmacol. 19, 225–234 (2008).
Schoepp, D. D., Wright, R. A., Levine, L. R., Gaydos, B. & Potter, W. Z. LY354740, an mGlu2/3 receptor agonist as a novel approach to trat anxiety/stress. Stress 6, 189–197 (2003).
Swanson, C. J., Bures, M., Johnson, M. P., Linden, A. M., Monn, J. A. & Schoepp, D. D. Metabotropic glutamate receptors as novel targets for anxiety and stress disorders. Nature Rev. Drug Discov. 4, 131–144 (2005).
Schoepp, D. D. & Marek, G. J. Preclinical pharmacology of mGlu2/3 receptor agonists: novel agents for schizophrenia? Curr. Drug Target CNS Neurol. Disord. 1, 215–225 (2002).
Conn, P. J., Tamminga, C., Schoepp, D. D. & Lindsley, C. Schizophrenia: moving beyond monoamine antagonists. Mol. Interv 8, 99–107 (2008b).
Grillon, C., Cordova, J., Levine, L. R. & Morgan, C. A. 3rd. Anxiolytic effects of a novel group II metabotropic glutamate receptor agonist (LY354740) in the fear-potentiated startle paradigm in humans. Psychopharmacology (Berl.) 168, 446–454 (2003).
Patil, S. T. et al. Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial. Nature Med. 13, 1102–1107 (2007).
Fell, M. J., Svensson, K. A., Johnson, B. G. & Schoepp, D. D. Evidence for the role of metabotropic glutamate (mGlu)2 not mGlu3 receptors in the preclinical antipsychotic pharmacology of the mGlu2/3 receptor agonist (−)-(1R, 4S, 5S, 6S)-4-amino-2-sulfonylbicyclo[3.1.0]hexane-4, 6-dicarboxylic acid (LY404039). J. Pharmacol. Exp. Ther. 326, 209–217 (2008).
Galici, R., Echemendia, N. G., Rodriguez, A. L. & Conn, P. J. A selective allosteric potentiator of metabotropic glutamate (mGlu) 2 receptors has effects similar to an orthosteric mGlu2/3 receptor agonist in mouse models predictive of antipsychotic activity. J. Pharmacol. Exp. Ther. 315, 1181–1187 (2005).
Johnson, M. P. et al. Discovery of allosteric potentiators for the metabotropic glutamate 2 receptor: synthesis and subtype selectivity of N-(4-(2-methoxyphenoxy)phenyl)-N-(2, 2, 2- trifluoroethylsulfonyl)pyrid-3-ylmethylamine. J. Med. Chem. 46, 3189–3192 (2003).
Lorrain, D. S. et al. Group II mGlu receptor activation suppresses norepinephrine release in the ventral hippocampus and locomotor responses to acute ketamine challenge. Neuropsychopharmacology 28, 1622–1632 (2003).
Schaffhauser, H. et al. Pharmacological characterization and identification of amino acids involved in the positive modulation of metabotropic glutamate receptor subtype 2. Mol. Pharmacol. 64, 798–810 (2003).
Pinkerton, A. B. et al. Allosteric potentiators of the metabotropic glutamate receptor 2 (mGlu2). Part 3: Identification and biological activity of indanone containing mGlu2 receptor potentiators. Bioorg Med. Chem. Lett. 15, 1565–1571 (2005).
Cube, R. V. et al. 3-(2-Ethoxy-4-{4-[3-hydroxy-2-methyl-4-(3-methylbutanoyl)phenoxy]butoxy}phenyl)propanoic acid: a brain penetrant allosteric potentiator at the metabotropic glutamate receptor 2 (mGluR2). Bioorg Med. Chem. Lett. 15, 2389–2393 (2005).
Galici, R. et al. Biphenyl-indanone A, a positive allosteric modulator of the metabotropic glutamate receptor subtype 2, has antipsychotic- and anxiolytic-like effects in mice. J. Pharmacol. Exp. Ther. 318, 173–185 (2006).
Rowe, B. A. et al. Transposition of three amino acids transforms the human metabotropic glutamate receptor (mGluR)-3 positive allosteric modulation site to mGluR2, and additional characterization of the mGluR2 positive allosteric modulation Site. J. Pharmacol. Exp. Ther. Apr 22 2008 (epub ahead of print).
Poisik, O. et al. Metabotropic glutamate receptor 2 modulates excitatory synaptic transmission in the rat globus pallidus. Neuropharmacology 49, 135–145 (2005).
Bennyworth, M. et al. A selective positive allosteric modulator of metabotropic glutamate receptor subtype 2 blocks a hallucinogenic drug model of psychosis. Mol. Pharmacol. 72, 477–484 (2007).
Lorrain, D. S., Baccei, C. S., Bristow, L. J., Anderson, J. J. & Varney, M. A. Effects of ketamine and N-methyl-D-aspartate on glutamate and dopamine release in the rat prefrontal cortex: modulation by a group II selective metabotropic glutamate receptor agonist LY379268. Neuroscience 117, 697–706 (2003a).
Moghaddam, B. & Adams, B. W. Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats. Science 281, 1349–1352 (1998).
Marek, G. J., Wright, R. A., Schoepp, D. D., Monn, J. A. & Aghajanian, G. K. Physiological antagonism between 5-hydroxytryptamine(2A) and group II metabotropic glutamate receptors in prefrontal cortex. J. Pharmacol. Exp. Ther. 292, 76–87 (2000).
Johnson, M. P. et al. Metabotropic glutamate 2 receptor potentiators: receptor modulation, frequency-dependent synaptic activity, and efficacy in preclinical anxiety and psychosis model(s). Psychopharmacology (Berl.) 179, 271–283 (2005).
Govek, S. P. et al. Benzazoles as allosteric potentiators of metabotropic glutamate receptor 2 (mGluR2): efficacy in an animal model for schizophrenia. Bioorg Med. Chem. Lett. 15, 4068–4072 (2005).
Conn, P. J., Battaglia, G., Marino, M. J. & Nicoletti, F. Metabotropic glutamate receptors in the basal ganglia motor circuit. Nature Rev. Neurosci. 6, 787–798 (2005).
Poewe, W. H., Lees, A. J. & Stern, G. M. Treatment of motor fluctuations in Parkinson's disease with an oral sustained-release preparation of L-dopa: clinical and pharmacokinetic observations. Clin. Neuropharmacol. 9, 430–439 (1986).
Wichmann, T. & DeLong, M. R. Functional neuroanatomy of the basal ganglia in Parkinson's disease. Adv. Neurol. 91, 9–18 (2003).
Bradley, S. R. et al. Activation of group II metabotropic glutamate receptors inhibits synaptic excitation of the substantia Nigra pars reticulata. J. Neurosci. 20, 3085–3094 (2000).
Valenti, O. et al. Group III metabotropic glutamate receptor-mediated modulation of the striatopallidal synapse. J. Neurosci. 23, 7218–7226 (2003).
Lopez, S. et al. Targeting group III metabotropic glutamate receptors produces complex behavioral effects in rodent models of Parkinson's disease. J. Neurosci. 27, 6701–6711 (2007).
Marino, M. J. et al. Allosteric modulation of group III metabotropic glutamate receptor 4: a potential approach to Parkinson's disease treatment. Proc. Natl Acad. Sci. USA 100, 13668–13673 (2003). Discovery of a novel mGluR4 PAM and demonstration that this compound has anti-parkinsonian activity in animal models.
Niswender, C. M. et al. Discovery, characterization, and antiparkinsonian effect of novel positive allosteric modulators of metabotropic glutamate receptor 4. Mol. Pharmacol. 74, 1345–1358 (2008).
Maj, M. et al. (−)-PHCCC, a positive allosteric modulator of mGluR4: characterization, mechanism of action, and neuroprotection. Neuropharmacology 45, 895–906 (2003).
Jones, P., Xiang, Z. & Conn, P. J. Metabotropic glutamate receptors mGluR4 and mGluR8 regulate transmission in the lateral olfactory tract-piriform. Neuropharmacol. (in the press).
Valenti, O., Mannaioni, G., Seabrook, G. R., Conn, P. J. & Marino, M. J. Group III metabotropic glutamate-receptor-mediated modulation of excitatory transmission in rodent substantia nigra pars compacta dopamine neurons. J. Pharmacol. Exp. Ther. 313, 1296–1304 (2005).
Ayala, J. E., Niswender, C. M., Luo, Q., Banko, J. L. & Conn, P. J. Group III mGluR regulation of synaptic transmission at the SC-CA1 synapse is developmentally regulated. Neuropharmacol. 54, 804–814 (2008).
Battaglia, G. et al. Pharmacological activation of mGlu4 metabotropic glutamate receptors reduces nigrostriatal degeneration in mice treated with 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine. J. Neurosci. 26, 7222–7229 (2006).
Mathiesen, J. M., Svendsen, N., Brauner-Osborne, H., Thomsen, C. & Ramirez, M. T. Positive allosteric modulation of the human metabotropic glutamate receptor 4 (hmGluR4) by SIB-1893 and MPEP. Br. J. Pharmacol. 138, 1026–1030 (2003).
Wess, J., Eglen, R. M. & Gautam, D. Muscarinic acetylcholine receptors: mutant mice provide new insights for drug development. Nature Rev. Drug Discov. 6, 721–733 (2007).
Clader, J. W. & Wang, Y. Muscarinic receptor agonists and antagonists in the treatment of Alzheimer's disease. Curr. Pharm. Des 11, 3353–3361 (2005).
Bymaster, F. P., Felder, C., Ahmed, S. & McKinzie, D. Muscarinic receptors as a target for drugs treating schizophrenia. Curr. Drug Targets. CNS Neurol. Disord. 1, 163–181 (2002).
Shekhar, A. et al. Selective muscarinic receptor agonist xanomeline as a novel treatment approach for schizophrenia. Am. J. Psychiatry 165, 1033–1039 (2008).
Greenlee, W. et al. Muscarinic agonists and antagonists in the treatment of Alzheimer's disease. Farmaco 56, 247–250 (2001).
Langmead, C. J. et al. Characterization of a CNS penetrant, selective M1 muscarinic receptor agonist, 77-LH-28–21 Br. J. Pharmacol. 154, 1104–1115 (2008).
Spalding, T. A. et al. Discovery of an ectopic activation site on the M(1) muscarinic receptor. Mol. Pharmacol. 61, 1297–1302 (2002).
Sur, C. et al. N-desmethylclozapine, an allosteric agonist at muscarinic 1 receptor, potentiates N-methyl-D-aspartate receptor activity. Proc. Natl Acad. Sci. USA 100, 13674–13679 (2003).
Lazareno, S. et al. Allosteric effects of four stereoisomers of a fused indole ring system with 3H-N-methylscopolamine and acetylcholine at M1-M4 muscarinic receptors. Life Sci. 64, 519–26 (1999).
Jones, C. K. et al. Novel selective allosteric activator of the M1 muscarinic acetylcholine receptor reduces amyloid processing and produces antipsychotic-like activity in rats. J. Neurosci. (in the press).
Chan, W. Y. et al.Allosteric modulation of the muscarinic M4 receptor as an approach to treating schizophrenia. Proc. Natl Acad. Sci. USA (in the press).
Shirey, J. K. et al. An allosteric potentiator of M4 mAChR modulates hippocampal synaptic transmission. Nature Chem. Biol. 4, 42–50 (2008). Together with reference 104, important studies identifying allosteric modulation of the M 4 muscarinic receptor as a novel approach for the treatment of CNS disorders.
Brady, A. et al. Centrally active allosteric potentiators of the M4 muscarinic acetylcholine receptor reverse amphetamine-induced hyperlocomotion behavior in rats. J. Pharmacol. Exp. Ther. (in the press).
Nawaratne, V. et al. New insights into the function of M4 muscarinic acetylcholine receptors gained using a novel allosteric modulator and a DREADD (designer receptor exclusively activated by a designer drug). Mol. Pharmacol. 74, 1119–1131 (2008).
Black, J. W. & Leff, P. Operational models of pharmacological agonism. Proc. R. Soc. Lond. B Biol. Sci. 220, 141–162 (1983).
Kenakin, T. Allosteric agonist modulators. J. Recept Signal Transduct. Res. 27, 247–259 (2007).
Gether, U. & Kobilka, B. K. G protein-coupled receptors. II. Mechanism of agonist activation. J. Biol. Chem. 273, 17979–17982 (1998).
Leppik, I. E. Antiepileptic drugs in development: prospects for the near future. Epilepsia 35, Suppl 4, 29–40 (1994).
Matsui, H., Lazareno, S. & Birdsall, N. J. Probing of the location of the allosteric site on m1 muscarinic receptors by site-directed mutagenesis. Mol. Pharmacol. 47, 88–98 (1995).
Gnagey, A. L., Seidenberg, M. & Ellis, J. Site-directed mutagenesis reveals two epitopes involved in the subtype selectivity of the allosteric interactions of gallamine at muscarinic acetylcholine receptors. Mol. Pharmacol. 56, 1245–1253 (1999).
Krejci, A. & Tucek, S. Changes of cooperativity between N-methylscopolamine and allosteric modulators alcuronium and gallamine induced by mutations of external loops of muscarinic M(3) receptors. Mol. Pharmacol. 60, 761–767 (2001).
Buller, S., Zlotos, D. P., Mohr, K. & Ellis, J. Allosteric site on muscarinic acetylcholine receptors: a single amino acid in transmembrane region 7 is critical to the subtype selectivities of caracurine V derivatives and alkane-bisammonium ligands. Mol. Pharmacol. 61, 160–168 (2002).
Voigtlander, U. et al. Allosteric site on muscarinic acetylcholine receptors: identification of two amino acids in the muscarinic M2 receptor that account entirely for the M2/M5 subtype selectivities of some structurally diverse allosteric ligands in N-methylscopolamine-occupied receptors. Mol. Pharmacol. 64, 21–31 (2003).
Huang, X. P., Prilla, S., Mohr, K. & Ellis, J. Critical amino acid residues of the common allosteric site on the M2 muscarinic acetylcholine receptor: more similarities than differences between the structurally divergent agents gallamine and bis(ammonio)alkane-type hexamethylene-bis-[dimethyl-(3-phthalimidopropyl)ammonium]dibromide. Mol. Pharmacol. 68, 769–778 (2005).
Prilla, S., Schrobang, J., Ellis, J., Holtje, H. D. & Mohr, K. Allosteric interactions with muscarinic acetylcholine receptors: complex role of the conserved tryptophan M2422Trp in a critical cluster of amino acids for baseline affinity, subtype selectivity, and cooperativity. Mol. Pharmacol. 70, 2181–2193 (2006).
Avlani, V., May, L. T., Sexton, P. M. & Christopoulos, A. Application of a kinetic model to the apparently complex behavior of negative and positive allosteric modulators of muscarinic acetylcholine receptors. J. Pharmacol. Exp. Ther. 308, 1062–1072 (2004).
Jakubik, J., Krejci, A. & Dolezal, V. Asparagine, valine, and threonine in the third extracellular loop of muscarinic receptor have essential roles in the positive cooperativity of strychnine-like allosteric modulators. J. Pharmacol. Exp. Ther. 313, 688–696 (2005).
Liaw, C. W., Grigoriadis, D. E., Lorang, M. T., De Souza, E. B. & Maki, R. A. Localization of agonist- and antagonist-binding domains of human corticotropin-releasing factor receptors. Mol. Endocrinol. 11, 2048–2053 (1997).
Dragic, T. et al. A binding pocket for a small molecule inhibitor of HIV-1 entry within the transmembrane helices of CCR5. Proc. Natl Acad. Sci. USA 97, 5639–5644 (2000).
Gerlach, L. O., Skerlj, R. T., Bridger, G. J. & Schwartz, T. W. Molecular interactions of cyclam and bicyclam non-peptide antagonists with the CXCR4 chemokine receptor. J. Biol. Chem. 276, 14153–14160 (2001).
Tsamis, F. et al. Analysis of the mechanism by which the small-molecule CCR5 antagonists SCH-351125 and SCH-350581 inhibit human immunodeficiency virus type 1 entry. J. Virol. 77, 5201–5208 (2003).
Rosenkilde, M. M. et al. Molecular mechanism of AMD3100 antagonism in the CXCR4 receptor: transfer of binding site to the CXCR3 receptor. J. Biol. Chem. 279, 3033–3041 (2004).
Maeda, K. et al. Spirodiketopiperazine-based CCR5 inhibitor which preserves CC-chemokine/CCR5 interactions and exerts potent activity against R5 human immunodeficiency virus type 1 in vitro. J. Virol. 78, 8654–8662 (2004).
Maeda, K. et al. Structural and molecular interactions of CCR5 inhibitors with CCR5. J. Biol. Chem. 281, 12688–12698 (2006).
Hemstapat, K., de Paulis, T., Chen, Y., Brady, A. E., Grover, V. K., Alagille, D., Tamagnan, G. D., Conn, P. J. A novel class of positive allosteric modulators of mGluR1 interact with a site distinct from that of negative allosteric modulators. Mol. Pharmacol. 70, 616–626 (2006).
Dupuis, D. S., Relkovic, D., Lhuillier, L., Mosbacher, J. & Kaupmann, K. Point mutations in the transmembrane region of GABAB2 facilitate activation by the positive modulator N, N'-dicyclopentyl-2-methylsulfanyl-5-nitro-pyrimidine-4, 6-diamine (GS39783) in the absence of the GABAB1 subunit. Mol. Pharmacol. 70, 2027–2036 (2006).
Pagano, A. et al. The non-competitive antagonists 2-methyl-6-(phenylethynyl)pyridine and 7-hydroxyiminocyclopropan[b]chromen-1a-carboxylic acid ethyl ester interact with overlapping binding pockets in the transmembrane region of group I metabotropic glutamate receptors. J. Biol. Chem. 275, 33750–33758 (2000).
Knoflach, F. et al. Positive allosteric modulators of metabotropic glutamate 1 receptor: characterization, mechanism of action, and binding site. Proc. Natl Acad. Sci. USA 98, 13402–13407 (2001).
Baez, M. et al. Molecular mapping of a subtype selective site for positive allosteric modulation of the mGlu2 receptor. Neuropharmacol. Abstr. 43, 274–275 (2002).
Malherbe, P. et al. Mutational analysis and molecular modeling of the allosteric binding site of a novel, selective, noncompetitive antagonist of the metabotropic glutamate 1 receptor. J. Biol. Chem. 278, 8340–8347 (2003).
Petrel, C. et al. Modeling and mutagenesis of the binding site of Calhex 231, a novel negative allosteric modulator of the extracellular Ca(2+)-sensing receptor. J. Biol. Chem. 278, 49487–49494 (2003).
Miedlich, S. U., Gama, L., Seuwen, K., Wolf, R. M. & Breitwieser, G. E. Homology modeling of the transmembrane domain of the human calcium sensing receptor and localization of an allosteric binding site. J. Biol. Chem. 279, 7254–7263 (2004).
Binet, V. et al. The heptahelical domain of GABA(B2) is activated directly by CGP7930, a positive allosteric modulator of the GABA(B) receptor. J. Biol. Chem. 279, 29085–29091 (2004).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
Dr Conn has received fees over the past 2 years as a consultant from: Merck and Co., Johnson and Johnson, Hoffman La Roche, Sepracor Inc., GlaxoSmithKline, Lundbeck Research USA, Epix Pharmaceuticals, Evotec Inc., Addex Pharmaceuticals, Seaside Therapeutics, AstraZeneca USA, NeurOp Inc., Forest Research Institute, Millipore Corp., Genentech and Otsuka. Dr Christopoulos has received fees as a consultant from: GlaxoSmithKline, Pfizer, Amgen, Bristol–Myers Squibb, Addex, Alchemia, Eli Lilly and Merck and Co. Dr Lindsley has received fees as a consultant from Amgen.
Related links
Glossary
- Orthosteric site
-
The binding site for the endogenous ligand on a receptor.
- Allosteric modulator
-
A ligand that binds to an allosteric site and modulates the binding and/or signalling of an orthosteric ligand.
- Allosteric site
-
A binding site on a receptor that is topographically distinct from the orthosteric site.
- Cooperativity
-
The binding of two or more molecules of the same ligand to a receptor complex to initiate a response. Also used in a less strict sense to describe the allosteric interaction between more than one molecule of any chemical type on a receptor complex.
- Stimulus-trafficking
-
The ability of a ligand to preferentially stabilize specific GPCR conformations, each associated with its own repertoire of stimuli and signalling behaviours, to the exclusion of other possible receptor states.
- Allosteric agonist
-
A ligand that binds to an allosteric site and causes receptor activation (allosteric agonist) or reduces constitutive receptor activity (allosteric inverse agonist) in the absence of an orthosteric ligand.
Rights and permissions
About this article
Cite this article
Jeffrey Conn, P., Christopoulos, A. & Lindsley, C. Allosteric modulators of GPCRs: a novel approach for the treatment of CNS disorders. Nat Rev Drug Discov 8, 41–54 (2009). https://doi.org/10.1038/nrd2760
Issue Date:
DOI: https://doi.org/10.1038/nrd2760
This article is cited by
-
The unconventional activation of the muscarinic acetylcholine receptor M4R by diverse ligands
Nature Communications (2022)
-
Update on GPCR-based targets for the development of novel antidepressants
Molecular Psychiatry (2022)
-
Coordination chemogenetics for activation of GPCR-type glutamate receptors in brain tissue
Nature Communications (2022)
-
An inpatient human laboratory study assessing the safety and tolerability, pharmacokinetics, and biobehavioral effect of GET 73 when co-administered with alcohol in individuals with alcohol use disorder
Psychopharmacology (2022)
-
Study of influence of the glutamatergic concentration of [18F]FPEB binding to metabotropic glutamate receptor subtype 5 with N-acetylcysteine challenge in rats and SRM/PET study in human healthy volunteers
Translational Psychiatry (2021)